ASCO

Combination of modified FOLFOXIRI/panitumumab also caused greater toxicity, study showed

Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread

"A win for a highly selected group of patients," says ASCO expert

Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy

Study shows 5-year local recurrence rate of 2.3% with lumpectomy and endocrine therapy alone

ORR quadrupled, median PFS nearly tripled with dabrafenib plus trametinib in low-grade disease

Chemotherapy adds little benefit in intermediate grade lesions

IV infusion could allow more patients to complete treatment regimen

No change in survival when combined with atezolizumab and chemotherapy

Circulating tumor DNA could determine who needs more therapy

First randomized support for strategy in progressive metastatic HR+/HER2- breast cancer

DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored

Chemo, RT, surgery avoided in short-term follow-up but study population was small

DESTINY-Breast04 extends agent's benefits to historically tough-to-treat disease